Industry
Biotechnology
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 30, 2024 | 2:53 pm
Portfolio Pulse from Benzinga Newsdesk
May 23, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 10:17 am
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 12:49 pm
Portfolio Pulse from Benzinga Insights
April 29, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 10, 2024 | 10:43 am
Portfolio Pulse from Avi Kapoor
April 09, 2024 | 5:12 pm
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 4:38 pm
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 11:56 am
Portfolio Pulse from Benzinga Newsdesk
April 08, 2024 | 10:31 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.